NTHL1 and endometrial cancer: Although the contribution of the SBS30 in endometrial cancer of patient #7 is somewhat lower compared to the CRCs of the pathogenic NTHL1 biallelic variant carriers (Figure 3), it remains the predominant observed signature in this tumor in spite of being evaluated in a different tumor type.